Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - October 01, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
3 Reasons Growth Investors Will Love Lilly (LLY)
by Zacks Equity Research
Lilly (LLY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication
by Zacks Equity Research
Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $148.10 in the latest trading session, marking a -1.44% move from the prior day.
Gilead & Galapagos' RA Drug Receives Approval in Europe
by Zacks Equity Research
Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.
Galapagos Gets First Commercial Drug With Jyseleca Approval
by Zacks Equity Research
Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.
Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan
by Zacks Equity Research
Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.
4 Reasons to Bet on Small-Cap ETFs Now
by Sanghamitra Saha
Small-cap stocks were hurt badly during the peak of the coronavirus-led lockdowns. Now, the gradual uptick of reopening trade has started to favor the small-cap spectrum.
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
by Kinjel Shah
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib
by Zacks Equity Research
The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $151.18, marking a -1.94% move from the previous day.
Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion
by Zacks Equity Research
Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody
by Zacks Equity Research
Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies
by Zacks Equity Research
Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
by Kinjel Shah
AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
Roche's Actemra Meets Goal in Phase III Coronavirus Study
by Zacks Equity Research
Roche's (RHHBY) phase III study, EMPACTA, evaluating Actemra in patients with COVID-19-associated pneumonia, meets primary endpoint.
No Rate Hike Until 2023: Here's How to Play With ETFs
by Sanghamitra Saha
As widely expected, the Fed held interest rates steady at a near-zero level in its latest meeting.
Lilly's Coronavirus Antibody Shows Positive Effect in Phase II
by Zacks Equity Research
Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.
Lilly Drug Gets Fast Track to Improve Heart Attack Outcome
by Zacks Equity Research
Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
by Zacks Equity Research
OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $150.08, moving +0.72% from the previous trading session.
Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study
by Zacks Equity Research
Eli Lilly (LLY) releases positive initial data from a phase III study evaluating Olumiant (baricitinib) in combination with Gilead's remdesivir for hospitalized patients with COVID-19.
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study
by Zacks Equity Research
Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.